Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Why Novavax Is Soaring Today

Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.